Synthetic cannabimimetic agents metabolized by carboxylesterases

Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry

(2014) Ariane Wohlfarth et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

UPLC/ESI-MS/MS-based determination of metabolism of several new illicit drugs, ADB-FUBINACA, AB-FUBINACA, AB-PINACA, QUPIC, 5F-QUPIC andα-PVT, by human liver microsome

(2014) Takahiro Takayama et al.   BIOMEDICAL CHROMATOGRAPHY

Four Postmortem Case Reports with Quantitative Detection of the Synthetic Cannabinoid, 5F-PB-22

(2014) George Behonick et al.   JOURNAL OF ANALYTICAL TOXICOLOGY

An Outbreak of Exposure to a Novel Synthetic Cannabinoid

(2014) Andrew A. Monte et al.   NEW ENGLAND JOURNAL OF MEDICINE

First Characterization of AKB-48 Metabolism, a Novel Synthetic Cannabinoid, Using Human Hepatocytes and High-Resolution Mass Spectrometry

(2013) Adarsh S. Gandhi et al.   AAPS Journal

First Metabolic Profile of XLR-11, a Novel Synthetic Cannabinoid, Obtained by Using Human Hepatocytes and High-Resolution Mass Spectrometry

(2013) A. Wohlfarth et al.   CLINICAL CHEMISTRY

Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products

(2013) Nahoko Uchiyama et al.   Forensic Toxicology

Carboxylesterase 1 Polymorphism Impairs Oseltamivir Bioactivation in Humans

(2012) E K Tarkiainen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Emerging Role of Human Esterases

(2012) Tatsuki Fukami et al.   Drug Metabolism and Pharmacokinetics

New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products

(2012) Nahoko Uchiyama et al.   Forensic Toxicology

Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity

(2012) Lucio G. Costa et al.   TOXICOLOGY

Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: Rifampicin, rifabutin, and rifapentine

(2011) Akinori Nakajima et al.   BIOCHEMICAL PHARMACOLOGY

Liquid Chromatography-Tandem Mass Spectrometry Analysis of Urine Specimens for K2 (JWH-018) Metabolites

(2011) M. A. ElSohly et al.   JOURNAL OF ANALYTICAL TOXICOLOGY

Beyond THC: The New Generation of Cannabinoid Designer Drugs

(2011) Liana Fattore et al.   Frontiers in Behavioral Neuroscience

Arylacetamide Deacetylase Is a Determinant Enzyme for the Difference in Hydrolase Activities of Phenacetin and Acetaminophen

(2010) A. Watanabe et al.   DRUG METABOLISM AND DISPOSITION

Identification of a Cannabinoid Analog as a New Type of Designer Drug in a Herbal Product

(2009) Nahoko Uchiyama et al.   CHEMICAL & PHARMACEUTICAL BULLETIN

Human Arylacetamide Deacetylase Is a Principal Enzyme in Flutamide Hydrolysis

(2009) A. Watanabe et al.   DRUG METABOLISM AND DISPOSITION

‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs?

(2009) Volker Auwärter et al.   JOURNAL OF MASS SPECTROMETRY

The Biotransformation of Prasugrel, a New Thienopyridine Prodrug, by the Human Carboxylesterases 1 and 2

(2008) E. T. Williams et al.   DRUG METABOLISM AND DISPOSITION

Effect of buffer components and carrier solvents on in vitro activity of recombinant human carboxylesterases

(2007) Eric T. Williams et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS